IP Library Granted Patent US 12,622,971
Granted Patent B2
US 12,622,971 · App. 17/489,128 · Granted May 12, 2026

Linear polysaccharide based film products

Inventors: Garry L. Myers (Kingsport, TN); Michael Li (Warren, NJ); Beuford Arlie Bogue (Warren, NJ); Eric Dadey (Sevierville, TN)
Assignee: Aquestive Therapeutics, Inc.
A61K47/36A61K9/006A61K31/4545A61K31/4985C08B37/0018A61K31/197A61K31/404A61K31/519
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,971
App. No.
17/489,128
Granted
May 12, 2026
Kind
B2
Abstract

Film products, especially suitable for oral delivery, which can be formed during manufacture in the form of large and/or heavy film strips or sheets and subsequently cut into uniform dosage units, each dosage unit being uniform in content and having distributed therein a linear polysaccharide, such as pullulan, a plasticizer, and an active component.

Claims (24)

1 . A cast film product comprising:

a self-supporting film composition comprising a matrix from which self-supporting unit doses can be formed, said matrix comprising:

(a) at least one linear polysaccharide film-forming polymer comprising pullulan in amounts of about 10% to about 35% by weight of the film composition;

(b) an active present in amounts of about 6% to about 65% by weight of the film composition;

and

(c) a plasticizer composition present in an amount of about 10% to about 45% by weight based on the combined weight of the plasticizer composition and a total polymer content in the film product;

said plasticizer composition comprising xylitol and glycerin, wherein the glycerin is present in an amount that is equal to or less than the amount of the xylitol by weight;

and said matrix further comprising a resin;

wherein substantially uniformly sized unit doses of the film composition exhibit a disintegration value in the range of about 1 second to about 60 seconds as measured by suspending the unit dose film such that half of the unit dose film is submerged in water at 37° C. and determining the time for the submerged half of the unit dose film to separate from the suspended half.

2 . The cast film product of claim 1 , wherein the plasticizer composition further comprises a plasticizer selected from the group consisting of propylene glycol, triacetin and sorbitol.

3 . The cast film product of claim 1 , further comprising a sugar alcohol selected from the group consisting of sorbitol and maltitol.

4 . The cast film product of claim 1 , wherein the amount of the glycerin is equal to the amount of xylitol by weight.

5 . The cast film product of claim 1 , wherein the xylitol is present in an amount of about 10% to about 45% by weight based on the combined weight of the xylitol and the total polymer content.

6 . The cast film product of claim 1 , wherein the plasticizer composition is present in an amount of about 15% to about 22.5% by weight based on the combined weight of the plasticizer composition and the total polymer content.

7 . The cast film product of claim 1 , wherein the plasticizer composition is present in an amount of about 18% to about 21% by weight based on the combined weight of the plasticizer composition and the total polymer content.

8 . The cast film product of claim 1 , wherein the unit dose film has a thickness of from about 3 μm to about 500 μm.

9 . The cast film product of claim 1 , wherein the active is a neuromuscular drug.

10 . The cast film product of claim 1 , further comprising an additional polymer.

11 . The cast film product of claim 10 , wherein the additional polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, starch, gelatin, and combinations thereof.

12 . The cast film product of claim 1 , further comprising an acid.

13 . The cast film product of claim 12 , wherein the acid is selected from the group consisting of citric acid, formic acid, acetic acid, propionic acid, ascorbic acid, lactic acid, malic acid, tartaric acid, and combinations thereof.

14 . The cast film product of claim 1 , wherein the unit doses exhibit a disintegration value in the range of about 2 to about 10 seconds as measured by suspending the unit dose film such that half of the unit dose film is submerged in water at 37° C. and determining the time for the submerged half of the unit dose film to separate from the suspended half.

15 . The cast film product of claim 1 , wherein the film product has a tensile strength of about 0.8 N/mm 2 .

16 . The cast film product of claim 1 , wherein the film product has a tensile strength of about 1 N/mm 2 .

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 075646/0258 →
SECURITY INTEREST Recorded May 12, 2026
From: AQUESTIVE THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075561/0782 →
SECURITY INTEREST Recorded Nov 2, 2023
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065446/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2021
From: MYERS, GARRY L.; LI, MICHAEL; BOGUE, BEUFORD ARLIE; DADEY, ERIC
To: MONOSOL RX, LLC
Reel/Frame 057643/0928 →
CHANGE OF NAME Recorded Sep 29, 2021
From: MONOSOL RX, LLC
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 057666/0845 →
Continuity (5)
Continuation 16830448 · Mar 26, 2020
Continuation 16002643 · Jun 7, 2018
Continuation 15534630
Provisional Application 62089676 · Dec 9, 2014
Related Publication 20220088201A1 · Mar 24, 2022
References Cited (20)
US 5948430A · Zerbe · 1999 [cited by examiner]
US 20060198873A1 · Chan et al. · 2006 [cited by applicant]
US 20060204559A1 · Bess · 2006 [cited by examiner]
US 20080057087A1 · Krumme · 2008 [cited by applicant]
US 20080233174A1 · Myers · 2008 [cited by examiner]
US 20100215774A1 · Maibach · 2010 [cited by applicant]
US 20130005831A1 · Rajewski · 2013 [cited by examiner]
US 20150025084A1 · Jeong et al. · 2015 [cited by applicant]
CA 2864322A1 · 2013 [cited by examiner]
CN 1829490A · 2006 [cited by applicant]
WO 0170194A1 · 2001 [cited by applicant]
WO 2005004989A2 · 2005 [cited by applicant]
WO WO2010146601A1 · 2010 [cited by examiner]
WO WO2012053006A2 · 2012 [cited by examiner]
WO 2013085224A1 · 2013 [cited by applicant]
WO 2016094567A1 · 2016 [cited by applicant]
Wu et al, Non-traditional plasticization of polymeric films, International Journal of Pharmaceutics 177 (1999), 15-27. (Year: 1999). [cited by examiner]
International Search Report dated Mar. 9, 2016 issued in PCT/US2015/064806 (3 pages). [cited by applicant]
Written Opinion of the International Searching Authority dated Mar. 9, 2016 issued in PCT/US2015/064806 (5 pages). [cited by applicant]
International Preliminary Report on Patentability dated Jun. 13, 2017 issued in PCT/US2015/064806 (6 pages). [cited by applicant]